Lonza Collaborates with Codiak to Acquire its Exosomes Manufacturing Facility in Lexington, Massachusetts (US)

Published: Nov 3, 2021 | Tags: Lonza, Codiak, Acquire, Exosomes Manufacturing Facility, Lexington, Massachusetts, US

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

Published: Nov 3, 2021 | Tags: Amylyx, NDA, US, FDA, AMX0035, ALS

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

Published: Nov 3, 2021 | Tags: uniQure, P- I/II, Study, AMT-130, Huntington Disease

Ionis Initiates P-III CORE Study of Olezarsen for the Treatment of Severe Hypertriglyceridemia

Published: Nov 3, 2021 | Tags: Ionis, P-III, CORE Study, Olezarsen, Severe Hypertriglyceridemia

Roche Entered into a Clinical Trial Supply Agreement with Galecto to Evaluate GB1211 + Tecentriq (atezolizumab) in P-IIa Trial for 1L Treatment of NSCLC

Published: Nov 3, 2021 | Tags: Roche, Galecto, GB1211, Tecentriq, atezolizumab, P-IIa, Trial, NSCLC

Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies

Published: Nov 3, 2021 | Tags: Novartis, Dunad, Oral Targeted, Protein Degrader Therapies

Moderna Entered into a Research and Development Collaboration with Metagenomi to Develop In Vivo Gene Editing Therapeutics

Published: Nov 2, 2021 | Tags: Moderna, Metagenomi, In Vivo Gene Editing Therapeutics, Genetic Diseases

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma

Published: Nov 2, 2021 | Tags: Antengene, NMPA, IND, Approval, P-Ib, MATCH Study, ATG-008, onatasertib, ATG-010, Selinexor, Diffuse Large B-Cell Lymphoma

AstraZeneca Reports Results of Saphnelo in P-III TULIP Clinical Trial Program for the Treatment of Systemic Lupus Erythematosus

Published: Nov 2, 2021 | Tags: AstraZeneca, Saphnelo, P-III, TULIP Clinical Trial Program, Systemic Lupus Erythematosus

Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 & 2 Trials for the Treatment of Active Psoriatic Arthritis

Published: Nov 2, 2021 | Tags: Janssen, Tremfya, guselkumab, P-III, DISCOVER-1, 2, Trials, Active Psoriatic Arthritis

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Published: Nov 2, 2021 | Tags: Junshi, Coherus, US, FDA, BLA, Toripalimab, Nasopharyngeal Carcinoma

Merck Entered into a WW Research Collaboration and License Agreement with Synthekine to Develop Novel Cytokine Therapeutics

Published: Nov 2, 2021 | Tags: Merck, Synthekine, Cytokine Therapeutics, Autoimmune Diseases

Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas

Published: Nov 1, 2021 | Tags: Incyte, US, FDA, NDA, Parsaclisib, R/R Non-Hodgkin Lymphomas

AstraZeneca to Divest Global Rights of Eklira and Duaklir to Covis Pharma in $270M Deal

Published: Nov 1, 2021 | Tags: AstraZeneca, Eklira, Duaklir, Covis Pharma, $270M

AstraZeneca and Hutchmed Initiate P-III SAMETA Trial of Imfinzi (durvalumab) + Orpathys (savolitinib) for Advanced Papillary Renal Cell Carcinoma

Published: Nov 1, 2021 | Tags: AstraZeneca, Hutchmed, P-III, SAMETA Trial, Imfinzi, durvalumab, Savolitinib, Advanced Papillary Renal Cell Carcinoma

Novartis’ Scemblix (asciminib) Receives the US FDA’s Approval for the Treatment of Chronic Myeloid Leukemia

Published: Nov 1, 2021 | Tags: Novartis, Scemblix, asciminib, US, FDA, Approval, Chronic Myeloid Leukemia

Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021

Published: Nov 1, 2021 | Tags: Merck, Keytruda, pembrolizumab, Studies, Melanoma, SMR 2021

Gilead Reports Interim Results of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in BICSTaR Study to Treat HIV

Published: Nov 1, 2021 | Tags: Gilead, Biktarvy, bictegravir, emtricitabine, tenofovir alafenamide, BICSTaR Study, HIV

Related Post: PharmaShots Weekly Snapshots (October 25 - 29, 2021)